SMARCD3

Across TCGA pan-cancer cohorts, SMARCD3 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SMARCD3 data layer compared with 22 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher SMARCD3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SMARCD3 expression acts as an unfavorable survival marker, although some lineages such as UCEC and OV show a favorable association.

ACC, HNSC, and UCEC are the cancer types where SMARCD3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.046	0.753	<.001	36	view →
HNSC	OS	Median	II,III,IV	0.214	0.744	<.001	36	view →
UCEC	DFS	Median	All	0.955	0.620	.022	20	view →
OV	OS	Median	III,IV	1.000	0.311	.042	6	view →
LGG	DFS	Median	All	0.161	0.753	<.001	6	view →
LIHC	OS	Median	II,III,IV	0.239	0.715	.035	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SMARCD3–ACC (DFS)

Open the ACC breakdown →